Temozolomide + radiotherapy: significant toxicity
- PDF / 123,169 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 10 Downloads / 189 Views
1
Temozolomide + radiotherapy: significant toxicity Temozolomide plus radiotherapy appears to be associated with a higher incidence of grade III or IV toxicity than radiotherapy alone in elderly patients with glioblastoma, according to results of a retrospective analysis. Researchers investigated the benefits and toxicities associated with the use of temozolomide given concurrently and adjuvantly with radiotherapy, compared with radiotherapy alone (given at diagnosis only) in 39 patients aged ≥ 65 years with newly diagnosed glioblastoma; 19 patients received temozolomide plus radiotherapy, and 20 received radiotherapy alone. Grade III or IV toxicity developed in 42% of temozolomide plus radiotherapy recipients, compared with no patients in the radiotherapy alone group (p = 0.001). Grade III or IV toxicities included γ-glutamyl transferase elevation (n = 1), pneumocystis pneumonia (1), urosepsis (1), inappropriate antidiuretic hormone secretion (1), fatigue (1) and myelosuppression (3). Median overall survival was longer in the temozolomide plus radiotherapy group, compared with the radiotherapy alone group (8.5 vs 5.2 months), but this may have been related to between-group differences in baseline characteristics (age at diagnosis, resection extent, and performance status). Furthermore, methylation of the MGMT gene promoter was not associated with longer overall survival. Sijben AE, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. Journal of Neuro-Oncology 89: 97-103, No. 1, Aug 801117209 2008
0114-9954/10/1217-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 30 Aug 2008 No. 1217
Data Loading...
